Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

Table 5 Summary of the additional costs involved in the use of vaccines containing whole-cell pertussis component (societal perspective)

Variable	First dose	Second dose	Third dose	Fourth dose	Total
HCP visits, hospitalizations and healthcare system costs	788,905	740,377	674,001	664,723	2,868,006
Pocket expenses, private vaccine payment	548,645	548,645	548,645	548,645	2,194,580
Transportations costs for adverse events	46,080	40,182	21,006	20,749	128,016
Absenteeism for parents for adverse events	686,022	598,436	317,221	304,666	1,906,345
Administration time for additional vaccine	269,567	269,567	266,730	263,542	1,069,406
Distribution costs of additional vaccine	35,561	35,561	35,187	34,766	141,075
Programmatic errors due to simultaneous vaccination^a	129,767	129,767	129,767	129,595	518,896
Cold chain costs for additional vaccine^b	3120	3120	3120	3120	12,480
Total	2,507,667	2,365,655	1,995,667	1,969,806	8,838,805

^aFor example, administration of all required vaccines at any scheduled visit may not be strictly according to the national schedule due to limits in stock availability or parental decision, which necessitates additional visits to receive all required vaccines (with their associated costs)
^bBased on assumption of the volume of both schemes; considering that the size of vaccination cohort would be same for the hexavalent, as well as the pentavalent plus polio vaccine programs, then there would be a space reduction of 50% (1 vaccine versus 2 vaccines). The calculation of the cost of the square meter (cold chain pallet) was based on the additional square meters required for pentavalent plus polio vaccine program according to the Chilean cohort
HCP Health Care Provider

ISSN: 1472-6963